UPMC Children's Community Pediatrics South Hills-Jefferson Hills
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bernhardson, Paul D
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Completed
3
943
Europe, US
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution
GlaxoSmithKline
Infections, Meningococcal
11/23
11/23
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
McDowell, Carley
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Meduna, Dave
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Muniz-Pujalt, Gysella
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25

Download Options